CI values for the effects of imatinib and ciclopirox or GC7 on cellular proliferation
| . | IC50 . | IC75 . | IC90 . |
|---|---|---|---|
| Imatinib + ciclopirox | |||
| K562 | 0.78 | 0.52 | 0.36 |
| BA/F3 p210 | 0.56 | 0.64 | 0.75 |
| BA/F3 351 | 1.10 | 0.79 | 0.61 |
| BA/F3 315 | 1.18 | 1.16 | 1.14 |
| Bcr-Abl+ HSCs | 0.51 | 0.47 | 0.50 |
| Imatinib + GC7 | |||
| K562 | 1.1 | 0.77 | 0.55 |
| BA/F3 p210 | 0.90 | 0.76 | 0.65 |
| BA/F3 351 | 0.77 | 0.67 | 0.69 |
| BA/F3 315 | 1.02 | 1.18 | 1.38 |
| Bcr-Abl+ HSCs | 0.70 | 0.72 | 0.76 |
| . | IC50 . | IC75 . | IC90 . |
|---|---|---|---|
| Imatinib + ciclopirox | |||
| K562 | 0.78 | 0.52 | 0.36 |
| BA/F3 p210 | 0.56 | 0.64 | 0.75 |
| BA/F3 351 | 1.10 | 0.79 | 0.61 |
| BA/F3 315 | 1.18 | 1.16 | 1.14 |
| Bcr-Abl+ HSCs | 0.51 | 0.47 | 0.50 |
| Imatinib + GC7 | |||
| K562 | 1.1 | 0.77 | 0.55 |
| BA/F3 p210 | 0.90 | 0.76 | 0.65 |
| BA/F3 351 | 0.77 | 0.67 | 0.69 |
| BA/F3 315 | 1.02 | 1.18 | 1.38 |
| Bcr-Abl+ HSCs | 0.70 | 0.72 | 0.76 |